Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long‐term analysis of 132 patients

Objectives:  In T1 bladder cancer (BC) multifocality, size of tumor (≥3 cm) and concomitant carcinoma in situ (CIS) are used to stratify patients' risk. We compared the long‐term results in patients with initial T1G3 bc treated with transurethral resection of the bladder (TURB), bacille Calmette‐Guérin (BCG) instillations and repeat resection with special regard to these clinical risk factors. The aim was to determine if they influence the outcome in the bladder sparing approach for initial T1G3 bc.

[1]  H. Herr,et al.  A re‐staging transurethral resection predicts early progression of superficial bladder cancer , 2006, BJU international.

[2]  Rudolf Hartung,et al.  The value of a second transurethral resection for T1 bladder cancer , 2006, BJU international.

[3]  J. Dunst,et al.  Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[5]  R. Millikan,et al.  The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. , 2006, The Journal of urology.

[6]  H. Herr.  Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. , 2005, The Journal of urology.

[7]  A. Orsola,et al.  Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. , 2005, European urology.

[8]  F. Burkhard,et al.  Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? , 2004, The Journal of urology.

[9]  M. Soloway,et al.  Contemporary management of stage T1 transitional cell carcinoma of the bladder. , 2002, The Journal of urology.

[10]  C. Sternberg,et al.  Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience. , 2002, Urology.

[11]  H. Habermann,et al.  Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? , 2002, Urology.

[12]  P. Sogani,et al.  Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? , 2001, The Journal of urology.

[13]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Loertzer,et al.  Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. , 2000, The Journal of urology.

[15]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[16]  J. Maranchie,et al.  Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant. , 2000, The Journal of urology.

[17]  D. Bostwick,et al.  Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer , 1999, Cancer.

[18]  A. Lembo,et al.  Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. , 1999, Urology.

[19]  T. Lebret,et al.  Low-Dose BCG Instillations in the Treatment of Stage T1 Grade 3 Bladder Tumours: Recurrence, Progression and Success , 1998, European Urology.

[20]  W. Otto,et al.  Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? , 2008, European urology.

[21]  L. Mazzucchelli,et al.  A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. , 2003, The Journal of urology.